Market research
MDC.AU Medlab Clinical Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15M
- P/E ratio
- 0.0
- Analyst target
- 18.84
- Dividend yield
- 0.0%
- Beta
- 0.91
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000MDC8
- Market cap
- 15M
- P/E ratio
- 0.0
- Analyst target
- 18.84
- Dividend yield
- 0.0%
- Beta
- 0.91
About
About Medlab Clinical Limited
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MDC.AU discussion.
5 years, 5 months ago
Medlab Clinical Limited is currently in a long term downtrend where the price is trading 31.8% below its 200 day moving average.
From a valuation standpoint, the stock is 93.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.4.
Medlab Clinical Limited's total revenue rose by 57.4% to $4M since the same quarter in the previous year.
Its net income has increased by 25.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.2% to $-2M since the same quarter in the previous year.
Based on the above factors, Medlab Clinical Limited gets an overall score of 4/5.